Anavar 10 - Aaster Solutions

Oxandrolone’s clinical introduction in 1962 by G.D. Searle & Co. marked a shift toward safer anabolic therapies. Marketed as Anavar, it supported muscle preservation and growth in patients facing chronic weight loss or developmental issues. Its unique profile allowed use across genders and age groups. Over time, misuse in sports drew public scrutiny, leading Searle to halt production in 1989. In 1995, the compound returned as Oxandrin under Bio-Technology General Corp., approved for rare medical conditions with the support of orphan drug legislation in the United States.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anavar 10 by Aaster Solutions, consult with your doctor or healthcare professional.